Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As part of an international collaboration, the DIL group will identify infants with a significant genetic risk for type 1 diabetes to begin recruiting for POInT, a randomized controlled phase IIb trial to determine if daily administration of high-dose oral insulin in early life can prevent T1D-associated autoimmunity.

Read the full article